Attached files
| file | filename |
|---|---|
| 8-K/A - 8-K/A - AMAG PHARMACEUTICALS, INC. | a14-26737_18ka.htm |
| EX-99.2 - EX-99.2 - AMAG PHARMACEUTICALS, INC. | a14-26737_1ex99d2.htm |
| EX-23.2 - EX-23.2 - AMAG PHARMACEUTICALS, INC. | a14-26737_1ex23d2.htm |
| EX-99.3 - EX-99.3 - AMAG PHARMACEUTICALS, INC. | a14-26737_1ex99d3.htm |
| EX-99.1 - EX-99.1 - AMAG PHARMACEUTICALS, INC. | a14-26737_1ex99d1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
AMAG Pharmaceuticals, Inc.
Waltham, Massachusetts
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-192132) and Form S-8 (File Nos. 333-82292, 333-131656, 333-148682, 333-159938, 333-168786, 333-182821, 333-190435 and 333-197873) of AMAG Pharmaceuticals, Inc. of our reports dated June 14, 2012, relating to the consolidated financial statements and the effectiveness of Lumara Health Inc.’s (formerly K-V Pharmaceutical Company) internal control over financial reporting, which are incorporated by reference in this Form 8-K/A. Our report on the consolidated financial statements dated June 14, 2012 contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
Chicago, Illinois
January 9, 2015